Développement de médicaments pour les maladies auto-immunes par l’usage thérapeutique du trioxyde d’arsenic.
Location: France, Great East, Strasbourg
Investors 1
| Date | Name | Website |
| - | Capital Gr... | capitalgra... |
Mentions in press and media 1
| Date | Title | Description |
| 25.10.2022 | Bone Therapeutics to start a new Euronext equity story with a change of name to BioSenic, following the acquisition of a majority participation of Medsenic valued at EUR 40 million | REGULATED INFORMATION New company’s pipeline enriched with serious inflammatory indications in addition to its original cell therapy asset New Chairman, Board Members and Management appointed 24,463,421 ALLOB subscription rights granted to ... |